Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 21, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 1,000,000 ordinary shares.
- Purchase Price: 1,470.866 pence per share.
- Treasury Shares Held: 255,027,678 shares (post-purchase).
- Shares in Issue: 5,752,443,941 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares due to the buyback of 1,000,000 shares on February 21, 2007. These shares are intended to be held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and conforms to the Transparency Directive's transitional provision 6.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,752,443,941) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the updated Treasury share count of 255,027,678.
- Note that this filing is a regulatory notification of a share buyback and does not contain quarterly or annual financial results.